The heightened attention that biopharma companies are paying to hot new technologies in the immuno-oncology and gene and cell therapy areas is translating to a significant increase in research and development investments being made by the sector. Drug discovery, however, does not come cheap, as evidenced from an in-depth analysis conducted by BioWorld.